MedTrace Logo

Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer

NCT02031042 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 224

Last updated 2019-10-28

No results posted yet for this study

Summary

The purpose of this study is to investigate if sentinel lymph node biopsy is a reliable staging tool for breast cancer patients planned for neoadjuvant chemotherapy (=before breast surgery) and if, in that case, it is safe to omit axillary lymph node dissection if the sentinel lymph node is free of metastasis.

Conditions

Sponsors & Collaborators

  • Swedish Breast Cancer Group

    collaborator OTHER

  • Stockholm South General Hospital

    lead OTHER

Principal Investigators

  • Linda H Zetterlund, PhD · Dep. of Medical Research and Education, Karolinska Institutet (KI), Stockholm, Sweden

  • Fuat Celebioglu, PhD · Dep. of Medical Research and Education, KI, Stockholm, Sweden

  • Jan Frisell, Professor · Dep. of Molecular Medicine and Surgery, KI, Stockholm, Sweden

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02031042 on ClinicalTrials.gov